Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Net Cash Flow (2016 - 2025)

Lexaria Bioscience's Net Cash Flow history spans 11 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 57.12% year-over-year to $2.5 million; the TTM value through Nov 2025 reached -$3.7 million, down 160.86%, while the annual FY2025 figure was -$4.6 million, 189.93% down from the prior year.
  • Net Cash Flow for Q4 2025 was $2.5 million at Lexaria Bioscience, up from -$2.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.8 million in Q1 2021 and bottomed at -$2.8 million in Q3 2025.
  • The 5-year median for Net Cash Flow is -$1.2 million (2021), against an average of $194381.9.
  • The largest annual shift saw Net Cash Flow crashed 200.0% in 2021 before it surged 3570.48% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$1.2 million in 2021, then dropped by 3.61% to -$1.3 million in 2022, then soared by 146.69% to $597691.0 in 2023, then surged by 164.61% to $1.6 million in 2024, then soared by 57.12% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Net Cash Flow are $2.5 million (Q4 2025), -$2.8 million (Q3 2025), and -$1.9 million (Q2 2025).